---
title: "CirculAting Tumor DNA in Patients DIagnosed With Lung Metastasis From Colorectal Cancer: candiDate Selection for Local AblaTive thErapy"
nct_id: NCT04704960
overall_status: UNKNOWN
sponsor: Yonsei University
study_type: OBSERVATIONAL
primary_condition: Colorectal Cancer
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04704960.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04704960"
ct_last_update_post_date: 2021-01-14
last_seen_at: "2026-05-12T06:55:07.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# CirculAting Tumor DNA in Patients DIagnosed With Lung Metastasis From Colorectal Cancer: candiDate Selection for Local AblaTive thErapy

**NCT ID:** [NCT04704960](https://clinicaltrials.gov/study/NCT04704960)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 400
- **Lead Sponsor:** Yonsei University
- **Conditions:** Colorectal Cancer, Lung Metastases
- **Start Date:** 2021-02
- **Completion Date:** 2023-12
- **CT.gov Last Update:** 2021-01-14

## Brief Summary

The investigators will detect circulating tumor DNA in blood of patients with lung metastases from colorectal cancer using NGS technology and intend to use it for predicting the outcome of local treatment (surgery or radiation) and recurrence of lung metastases.

## Detailed Description

The investigators produce customized gene target panel by selecting genes that are commonly found in colorectal cancer and metastasis from existing literature.

In patients diagnosed with lung metastases from colorectal cancer, 20mL of whole blood is collected before and after local treatment (surgery or radiation) and cell-free DNA (cfDNA) is extracted from the collected blood. Thereafter, 20 mL of whole blood is additionally collected once after 3 months (±2 months) and once after 6 months (±2 months) during follow-up and cfDNA is extracted. The investigators perform sequencing from the extracted cfDNA.

The investigators compare the mutations detected in cfDNA before and after local treatment and identify the trend of reducing mutations in cfDNA after local treatment. So The investigators discover biomarkers for the outcome of local treatment. The investigators also search for mutations for target drugs from mutation profiling of cfDNA.

## Eligibility

- **Minimum age:** 19 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. adults over 19 years of age
2. those who understand research and have written consent
3. cases diagnosed with lung metastases from colorectal cancer

Exclusion Criteria:

1. pregnant women, nursing women
2. those who lack the ability to voluntarily agree
3. participation in other clinical trials where drugs for clinical trials are administered within the past four weeks as of the date of participation in clinical trials
```

## Arms

- **Lung metastases from colorectal cancer, local ablative therapy (surgery or radiation)** — patients diagnosed with lung metastases from colorectal cancer and undergoing surgery or radiation for lumg metastasis

## Interventions

- **Diagnostic Test: liquid biopsy** (OTHER) — detection of tumor DNA alteration in cf-DNA

## Primary Outcomes

- **correlation between circulating tumor DNA (ctDNA) before and after local treatment (surgery or radiation) and recurrence of lung metastases from colorectal cancer** _(time frame: about 6 month but additional extension for patients with relapse after local treatment)_ — The investigations investigate whether ctDNA changes and f/u ctDNA fraction after local treatment (surgery or radiation) can be useful as markers to predict the outcome of local treatments.

## Secondary Outcomes

- **mutations related to target drug** _(time frame: about 6 month but additional extension for patients with relapse after local treatment)_

## Locations (1)

- Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, South Korea

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of laboratory medicine, yonsei university college of medicine|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04704960.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04704960*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*